non-hodgkin lymphoma

From the Field
Real-World Characteristics and Outcomes of Patients With Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Treated With First-Line Bendamustine + Rituximab
04/20/2022
Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.
Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.
Dr Kotchetkov and colleagues...
04/20/2022
Journal of Clinical Pathways
News
Reduced-Intensity Conditioning Regimens for Patients With NHL Undergoing Transplant
06/09/2020
Use of a more intense reduced-intensity conditioning and non-myeloablative conditioning (RIC-NMAC) regimen for allogeneic hematopoietic cell transplant (HCT) in patients with non-Hodgkin lymphoma should be considered...
Use of a more intense reduced-intensity conditioning and non-myeloablative conditioning (RIC-NMAC) regimen for allogeneic hematopoietic cell transplant (HCT) in patients with non-Hodgkin lymphoma should be considered...
Use of...
06/09/2020
Journal of Clinical Pathways
Research in Review
CAR-T Therapy Response Independent of Disease Factors in NHL
07/10/2017
JCP Editors
A recent clinical trial of a chimeric antigen receptor (CAR) T-cell therapy showed a significantly high response rate in treatment-resistant and relapsed aggressive non-Hodgkin lymphoma (NHL) independent of disease...
A recent clinical trial of a chimeric antigen receptor (CAR) T-cell therapy showed a significantly high response rate in treatment-resistant and relapsed aggressive non-Hodgkin lymphoma (NHL) independent of disease...
A...
07/10/2017
Journal of Clinical Pathways
Research in Review
High Response Rates With New Treatment for Aggressive B-Cell Lymphoma
06/13/2017
JCP Editors
In a recent trial, researchers determined complete response rates in patients with aggressive B-cell lymphomas after treatment with new a CAR T-cell product. ----- Related Content B-Cell ALL Disease Burden May...
In a recent trial, researchers determined complete response rates in patients with aggressive B-cell lymphomas after treatment with new a CAR T-cell product. ----- Related Content B-Cell ALL Disease Burden May...
In a...
06/13/2017
Journal of Clinical Pathways
Research in Review
Polypharmacy and Inappropriate Medications Negatively Impact Older Patients With NHL
06/07/2017
JCP Editors
Older patients with non-Hodgkin lymphoma (NHL) who take potentially inappropriate medications increase the risk of adverse survival impacts, according to research presented at the 2017 ASCO Annual Meeting (June 2-6,...
Older patients with non-Hodgkin lymphoma (NHL) who take potentially inappropriate medications increase the risk of adverse survival impacts, according to research presented at the 2017 ASCO Annual Meeting (June 2-6,...
Older...
06/07/2017
Journal of Clinical Pathways
Research in Review
ASCT Deemed Safe and Effective for Older Patients With B-Cell Malignancies
05/25/2017
JCP Editors
Older patients with B-cell malignancies benefit from progression-free survival (PFS) and overall survival (OS) improvements after autologous stem cell transplantation (ASCT), according to research that will be...
Older patients with B-cell malignancies benefit from progression-free survival (PFS) and overall survival (OS) improvements after autologous stem cell transplantation (ASCT), according to research that will be...
Older...
05/25/2017
Journal of Clinical Pathways
Research in Review
Triple Combination Active in High-Risk B-Cell Malignancies
05/24/2017
JCP Editors
A combination of 3 pathway inhibitors is well tolerated with activity observed in heavily pre-treated and high-risk B-cell malignancies, according to research that will be presented at the ASCO Annual Meeting (June...
A combination of 3 pathway inhibitors is well tolerated with activity observed in heavily pre-treated and high-risk B-cell malignancies, according to research that will be presented at the ASCO Annual Meeting (June...
A...
05/24/2017
Journal of Clinical Pathways
Research in Review
CAR T-Cells Offer Biomarker for Objective Response in Non-Hodgkin Lymphoma
04/28/2017
JCP Editors
The ability of chimeric antigen receptor (CAR) T-cells to perform multiple functions is associated with improved outcomes for patients with advanced non-Hodgkin lymphoma, offering a biomarker for response, according...
The ability of chimeric antigen receptor (CAR) T-cells to perform multiple functions is associated with improved outcomes for patients with advanced non-Hodgkin lymphoma, offering a biomarker for response, according...
The...
04/28/2017
Journal of Clinical Pathways
Research in Review
Serum Marker Helps Predict Response to CAR-T Therapy in Lymphoma
04/28/2017
JCP Editors
Patients with relapsed or refractory lymphoma who achieve durable remission after low-dose conditioning chemotherapy and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tend to have high serum levels of a...
Patients with relapsed or refractory lymphoma who achieve durable remission after low-dose conditioning chemotherapy and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tend to have high serum levels of a...
...
04/28/2017
Journal of Clinical Pathways
Feature
Positioning CAR-T Therapy Into Clinical Pathways for Non-Hodgkin B-Cell Lymphoma and Beyond
03/23/2017
Abstract: Enthusiasm for immunotherapy has spread throughout the oncology community in recent years, as therapies harnessing the body’s ability to fight cancers have offered the potential for remission and even cure...
Abstract: Enthusiasm for immunotherapy has spread throughout the oncology community in recent years, as therapies harnessing the body’s ability to fight cancers have offered the potential for remission and even cure...
...
03/23/2017
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use